Last reviewed · How we verify
Mupirocin ointment
At a glance
| Generic name | Mupirocin ointment |
|---|---|
| Also known as | Mupirocin Nasal Product, Bactroban, Control, Centany |
| Sponsor | Indiana University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Burning, stinging, or pain
- Itching
Serious adverse events
- Anaphylaxis
- Systemic allergic reactions
- Angioedema
- Urticaria
- Generalized rash
- Clostridium difficile-associated diarrhea
- Eye irritation
- Contact dermatitis
Key clinical trials
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- Staph Household Intervention for Eradication (SHINE) (PHASE4)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
- Bacterial Decolonization Within Dyads (NA)
- Optimal Treatment of MRSA Throat Carriers (PHASE3)
- The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal (PHASE3)
- Efficacy of Hydrocolloid Dressing vs. Topical Antibiotic on Wound Healing of Post-Punch Biopsy Wounds (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mupirocin ointment CI brief — competitive landscape report
- Mupirocin ointment updates RSS · CI watch RSS
- Indiana University portfolio CI